
Astellas Pharma announces new senior hires
pharmafile | August 7, 2014 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Astellas
Astellas Pharma EMEA, the European division of Astellas Pharma, has appointed Simon Dew to the position of chief strategy officer and Jun Kono (pictured) to the role of VP of corporate strategy and communications.
Dew succeeds Naoki Okamura, who after more than two years in the post has moved to the company’s global headquarters in Tokyo as corporate VP of licensing and alliances.
He comes from his previous role as vice president of business and commercial development.
In his new role Dew will oversee business development, alliance management, commercial development, and corporate strategy and communications, leading a team of around 18 specialists across these functions.
Meanwhile Kono takes on leadership of Astellas Pharma EMEA’s corporate strategy and communications, and will be responsible for guiding the strategic direction of the company’s mid-term plan, product portfolio and commercial operations.
He will also lead development of Astellas’ growing profile in the EMEA region, building the company’s corporate brand through communications targeting a wide-range of internal and external stakeholders.
In addition, Kono will be responsible for planning and directing Astellas Pharma EMEA’s programme of corporate social responsibility (CSR) initiatives.
Related Content

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration …

EMA accepts Astellas’ MAA for Zolbetuximab
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing …

Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders
Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have …






